← SynDRA
LY-2090314
SynDRA canonical compound SYN0005685 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | GSK3B |
|---|
| Mechanism of action | glycogen synthase kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- GSK3B INHIBITOR
- Glycogen synthase kinase-3 beta inhibitor
- GSK3A INHIBITOR
- Glycogen synthase kinase-3 alpha inhibitor
- glycogen synthase kinase inhibitor
- GSK3A MODULATOR
- GSK3B MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CDK2
- CDK4
- PRKCB
- PDK1
- PKN2
- PIM3
- PIM1
- PHKG2
- PDPK1
- PBK
- PAK4
- AKT1
- PLK3
- PAK1
- NTRK2
- NEK4
- NEK2
- MINK1
- MARK3
- MARK2
- MAPKAPK3
- MAPKAPK2
- PLK1
- PRKACA
- PRKAA1
- MAPK8
- TAOK1
- STK3
- STK17A
- SRPK1
- SLK
- SGK2
- RPS6KB1
- RPS6KA3
- ROCK2
- ROCK1
- PRKD3
- PRKD2
- PRKCZ
- PRKCI
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AAPK1
- COMT
- SYK
- ST17A
- PNMT
- PARP1
- NTMT1
- NTM1A
- NSD2
- NNMT
- KSYK
- KS6A3
- KPCG
- KPCD
- KCC2G
- KCC2D
- KCC2B
- IFNG
- IFNB1
- HNMT
- GNMT
- GAMT
- DYR1A
- CP3A7
- CP2C9
- TP53
Cross-references
Synonyms
- LY 2090314
- LY2090314
- UNII-822M3GYM67
- Kinome_3681
- CHEMBL362558
- 822M3GYM67
- 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione
- SCHEMBL633455
- GTPL7958
- DTXSID90209085
- MolPort-035-944-332
- EX-A2214
- ZINC3817327
- BCP07855
- s7063
- BDBM50150699
- AKOS032950045
- AKOS026750195
- CS-1633
- DB11913
- SB16558
- NCGC00378942-05
- NCGC00378942-02
- BC600682
- QC-11735
- HY-16294
- KB-78238
- FT-0698670
- LY2090314, >
- ly2090314
- CHEBI:167661
- HMS3673E17
- HMS3747E07
- MFCD20526532
- NSC772198
- NSC801005
- CCG-269790
- NSC-772198
- NSC-801005
Look up LY-2090314 in the interactive SynDRA portal →